CCF Medical Assistance Programmes

Cumulative approved number of applications & subsidy amount (up to 31 January 2020) 


(a) The First Phase Programme (for Specified Self-financed Cancer Drugs)


Drugs and designated type of cancer No. of applications approved Amount of subsidies granted
(HK Dollar)
Pemetrexed N4 for treating lung cancer 2,362 $87.79M
Sunitinib for treating gastrointestinal tumour 209 $16.84M
Sunitinib for treating renal cell carcinoma 369 $24.92M
Pegylated liposomal Doxorubicin for treating ovarian cancer 316 $14.22M
Lapatinib for treating breast cancer 615 $31.18M
CetuximabN2for treating colorectal cancer 163 $15.57M
RituximabN1for treating leukaemia 22 $1.10M
DasatinibN1for treating leukaemia 5 $0.16M
GefitinibN3 for treating lung cancer 3,227 $271.37M
Sorafenib for treating liver cancer 2,155 $72.84M
ErlotinibN3for treating lung cancer 1,745 $141.14M
PazopanibN5for treating renal cell carcinoma 254 $24.85M
AfatinibN3for treating lung cancer 129 $11.81M
BendamustineN6for treating leukaemia 22 $3.18M
TrastuzumabN6for treating gastric carcinoma 32 $4.58M
VemurafenibN6for treating skin cancer 16 $2.47M
Bevacizumab for treating epithelial ovarian / fallopian tube / primary peritoneal cancer N7 91 $13.08M
PertuzumabN7 for treating breast cancer 318 $116.55M
AbirateroneN14 for treating Prostate cancer 91 $10.33M
EnzalutamideN12 for treating Prostate cancer 170 $22.19M
NivolumabN8for treating skin cancer 31 $8.73M
ObinutuzumabN8for treating chronic lymphocytic leukaemia 14 $1.62M
BevacizumabN9for treating colorectal cancer 510 $54.32M
AxitinibN10for treating renal cell carcinoma 26 $1.21M
AlectinibN10for treating lung cancer 42 $11.80M
CeritinibN10for treating lung cancer 17 $2.05M
OsimertinibN10for treating lung cancer 185 $48.73M
PalbociclibN10for treating breast cancer 131 $27.73M
EverolimusN10for treating breast cancer 26 $3.49M
Trastuzumab emtansineN10for treating breast cancer 61 $15.48M
RibociclibN11for treating breast cancer 21 $3.99M
Dabrafenib and TrametinibN13for treating skin cancer 0 $0M
Total 13,375 $1,065.32M

N1 Repositioned to the Samaritan Fund with effect from 13 April 2013 and the above figures are based on the actual drug expenditure.
N2 Repositioned to the Samaritan Fund with effect from 1 August 2016 and the above figures are based on the actual drug expenditure.
N3 Repositioned to the Samaritan Fund with effect from 16 February 2019 and the above figures are based on the actual drug expenditure.
N4 Repositioned to the Special Drugs under HA Drug Formulary with effect from 13 April 2019 and the above figures are based on the actual drug expenditure.
N5 Introduced to the First Phase Programme with effect from 1 August 2015.
N6 Introduced to the First Phase Programme with effect from 1 August 2016.
N7 Introduced to the First Phase Programme with effect from 1 August 2017.
N8 Introduced to the First Phase Programme with effect from 1 August 2018.
N9 Introduced to the First Phase Programme with effect from 1 August 2013 and indication extended with effect from 1 August 2018.
N10 Introduced to the First Phase Programme with effect from 16 February 2019.
N11 Introduced to the First Phase Programme with effect from 13 July 2019.
N12 Introduced to the First Phase Programme with effect from 1 August 2017 and indication extended with effect from 13 July 2019.
N13 Introduced to the First Phase Programme with effect from 11 January 2020.
N14 Introduced to the First Phase Programme with effect from 1 August 2017 and indication extended with effect from 11 January 2020.


(b) The Programme “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)” (with effect from 1 August 2017)


Drugs and designated clinical indication No. of applications approved Amount of subsidies granted
(HK Dollar)
Eculizumab for treating Paroxysmal Nocturnal Haemoglobinuria 28 $101.19M
Eculizumab for treating Atypical Haemolytic Uraemic SyndromeN15 3 $10.73M
Nusinersen for treating Spinal Muscular AtrophyN16 14 $37.15M
Tafamidis for treating Transthyretin Familial Amyloid PolyneuropathyN17 1 $0.88M
Total 46 $149.95M

N15 Introduced to the Programme with effect from 25 November 2017.
N16 Introduced to the Programme with effect from 25 September 2018.
N17 Introduced to the Programme with effect from 13 July 2019.

(c) The Programme “Subsidy for Eligible Patients of Hospital Authority to Purchase Specified Implantable Medical Devices for Interventional Procedures”(with effect from 1 August 2017)

Implantable medical devices No. of applications approved Amount of subsidies granted
(HK Dollar)
Transcatheter Aortic Valve Implantation (TAVI) 80 $22.93M
MitraClip System 29 $7.14M
Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)N18 25 $5.42M
Percutaneous Pulmonary Valve Implantation (PPVI)N18 2 $0.60M
Impella for high-risk PCI ProceduresN19 31 $7.00M
Valve-in-valve Transcatheter Aortic Valve Implantation (VIV - TAVI)N20 0 $0M
Total 167 $43.09M

N18 Introduced to the Programme with effect from 1 August 2018.
N19 Introduced to the Programme with effect from 16 February 2019.
N20 Introduced to the Programme with effect from 13 July 2019.